Dr. Urs Heimgartner
Dr. Urs Heimgartner has joined MHHC GmbH as a partner and serves as the Chief Administrative and Financial Officer.
He was employed at Bayer (Schweiz) AG for 26 years, fulfilling various roles, most recently as Head of Market Access.
He has hands-on experience in bringing innovative products to the market, despite challenging environments,
and securing their placement on the Reimbursement List (SL) of the BAG.
Previously, he held the position of Business Unit Manager for Oncology and Hematology,
where he successfully launched numerous pharmaceutical products,
including Xarelto, Xofigo, Adempas, Stivarga, and Kogenate SF.
Dr. Urs Heimgartner holds a PhD in Biotechnology from ETH Zürich and is a Market Access Consultant at Target BioScience AG.
